GlassScriptPhysician profile
Jose A Cardenas
NPI 1245279314
$215,768.33
in general payments reported to CMS, 2019-2025
65 companies · $4,926 in 2025
The $4,926 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $28K · 2021: $53K · 2022: $40K · 2023: $13K · 2024: $6,798 · 2025: $4,926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $10K · Consulting Fee: $1,500 · Travel and Lodging: $45.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,300.00 |
| Food and Beverage | $10,036.60 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $45.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59,382.01 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Abbvie INC. | $42,025.08 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Amgen INC. | $39,707.26 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $23,173.80 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $20,917.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15,195.23 | 2021 | |
| Lundbeck LLC | $2,453.86 | 2019-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $1,081.77 | 2019-2025 | Nuplazid |
| Sk Life Science, INC. | $975.86 | 2020-2025 | Xcopri |
| Ucb, INC. | $952.24 | 2019-2025 | Fintepla, Rystiggo, Briviact |
| Neurocrine Biosciences, INC. | $943.42 | 2020-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $727.18 | 2019-2022 | |
| Pfizer INC. | $654.77 | 2021-2025 | |
| Emd Serono, INC. | $634.19 | 2021-2025 | Mavenclad |
| Eisai INC. | $559.72 | 2019-2025 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Cardenas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.